The estimated Net Worth of Joseph C Jr Cook is at least $2.69 Milion dollars as of 19 March 2015. Joseph Cook owns over 92,270 units of Ironwood Pharmaceuticals Inc stock worth over $1,551,071 and over the last 19 years Joseph sold IRWD stock worth over $1,137,371.
Joseph has made over 18 trades of the Ironwood Pharmaceuticals Inc stock since 2005, according to the Form 4 filled with the SEC. Most recently Joseph sold 92,270 units of IRWD stock worth $481,649 on 19 March 2015.
The largest trade Joseph's ever made was buying 670,162 units of Ironwood Pharmaceuticals Inc stock on 6 February 2009 worth over $462,412. On average, Joseph trades about 64,690 units every 76 days since 2005. As of 19 March 2015 Joseph still owns at least 356,568 units of Ironwood Pharmaceuticals Inc stock.
You can see the complete history of Joseph Cook stock trades at the bottom of the page.
Joseph's mailing address filed with the SEC is C/O CORCEPT THERAPEUTICS INCORPORATED, 275 MIDDLEFIELD ROAD, SUITE A, MENLO PARK, CA, 94025.
Over the last 15 years, insiders at Ironwood Pharmaceuticals Inc have traded over $83,928,361 worth of Ironwood Pharmaceuticals Inc stock and bought 2,478,676 units worth $24,100,589 . The most active insiders traders include Llc Fmr, Bryan E Roberts a Alexander J Denner. On average, Ironwood Pharmaceuticals Inc executives and independent directors trade stock every 19 days with the average trade being worth of $239,611. The most recent stock trade was executed by Minardo John on 12 August 2024, trading 9,910 units of IRWD stock currently worth $42,316.
ironwood pharmaceuticals (nasdaq: irwd) is focused on creating medicines that make a difference for patients, building value to earn the continued support of our fellow shareholders, and empowering our passionate team to keep doing these two things again and again as we continue to build a leading gastrointestinal therapeutics company. we discovered, developed and are commercializing a medicine for the treatment of adults suffering from irritable bowel syndrome with constipation (ibs-c) or chronic idiopathic constipation (cic). we are also developing a rich pipeline of programs seeking to address patient needs across the upper and lower gastrointestinal tract. our pipeline priorities include exploring further opportunities for our lead medicine, as well as leveraging our therapeutic expertise in gastrointestinal disorders and our pharmacologic expertise in guanylate cyclases to advance multiple investigational medicines. ironwood was founded in 1998 out of the whitehead institute for b
Ironwood Pharmaceuticals Inc executives and other stock owners filed with the SEC include: